Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 10.00 (5.128%)
Market Cap: £34.01m
SNX Live PriceLast checked at - London Stock Exchange

Intraday Synectics Share Chart

Director/PDMR Shareholding

10 Oct 2012 09:52

RNS Number : 3685O
Synectics PLC
10 October 2012
 



Synectics plc

(the "Company" or the "Group")

 

Award of Options under Revised Share Plan

Director PDMR shareholding

 

 

Synectics plc (AIM: SNX), a leader in the design, integration and control of advanced surveillance technology and networked security systems, announces that on 9 October 2012 it adopted a revised Executive Share Ownership Plan (the "Revised ExSOP") for Group executives, to replace its existing Executive Share Ownership Plan (the "existing ExSOP"), and made awards over 142,250 ordinary shares of 20p (the "Shares") to certain senior managers employed within the Group.

 

Under the Revised ExSOP, selected employees are entitled to exercise an option to receive a certain number of Synectics shares at any time after a 3 year vesting period, at no cost to themselves. The number of shares that are awarded at the end of the 3 year period is dependent on the achievement of certain performance criteria.

 

The performance criteria are identical to those that apply under the existing ExSOP. Provided that the total return on Synectics shares has out-performed the AIM All Share Total Return Index (the "Index") by 5% or more in the three years following the award, beneficiaries will be entitled to receive the full number of shares awarded. If Synectics' share performance matches the Index, then 25% of the awarded shares will vest and between these points vesting will be pro-rata. If the total return on Synectics shares underperforms the Index, then no entitlement will vest. The limit on the number of shares over which interests may be awarded also remains unchanged.

 

Any entitlement under the Revised ExSOP will lapse on cessation of employment prior to the end of the three year vesting period unless this is by reason of redundancy, ill health or death.

 

It is intended that if the performance criteria are met in full or part, the appropriate number of Shares will be transferred to the employees from unallocated Synectics shares already held within the employee benefit trust established for the existing ExSOP. 

 

Full details of the Revised ExSOP will be set out in the Company's Annual Report for the year ending 30 November 2012 which is expected to be issued in March 2013.

 

As a result of the award of options over the Shares referred to above, John Shepherd and Nigel Poultney, directors of the Company, have acquired an interest in 15,000 and 10,000 Synectics shares respectively.

 

In addition the Company has been notified that the Trustee of the Company's HMRC Approved Employee Share Acquisition Plan ("ESAP") has today purchased, in accordance with the ESAP's rules and on behalf of all ESAP participants, 6,547 ordinary shares of 20 pence each in the Company ("Ordinary Shares"), at a price of 272.5 pence each.

 

Under the terms of the ESAP, participating members, including employees and certain Directors of the Company, contribute a fixed amount to the Trustee on a monthly basis. The Trustee acquires a number of shares in the Company at the end of the contribution period (the "Period") (normally 6 months) based upon the contributions made in the preceding period and determined by the lowest share price at either the beginning of the Period or on the purchase day. In this instance the share price used for ESAP purposes was the price on the purchase day.

 

The Company was also notified that the above number of Ordinary Shares acquired by the Trustee included 189 Ordinary Shares, purchased as part of the reinvestment of the Company's interim dividend.  

 

As a result of these purchases, John Shepherd and Nigel Poultney, directors of the Company, have each acquired an interest in 289 Synectics shares.

 

 

 

Following the award of options over the Shares referred to above, and the share purchases in relation to the ESAP, the interests of John Shepherd and Nigel Poultney in Synectics shares are as follows:

 

Director

Position

B

Beneficial Interest

Interest in Share Schemes

ResultantTotalInterest

% ofIssuedShare Capital

John Shepherd

Chief Executive

58,972

402,202

461,174

2.62%

Nigel Poultney

Finance Director

13,000

221,864

234,864

1.34%

.

 

For further information, please contact:

Synectics plc

Tel: +44 (0) 1527 850080

Peter Rae, Senior Independent Director

www.synecticsplc.com

Westhouse Securities Limited

Tel: +44 (0) 207 601 6100

Tom Griffiths

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAPEEFSEAFEF
Date   Source Headline
10th May 20114:14 pmRNSHolding(s) in Company
10th May 20119:53 amRNSHolding(s) in Company
5th May 20113:17 pmRNSResult of AGM
4th May 20117:00 amRNSAGM Statement
15th Apr 201110:00 amRNSHolding(s) in Company
8th Apr 20113:39 pmRNSDirector Shareholding
7th Apr 20117:00 amRNSAGM - Date Change
30th Mar 20114:35 pmRNSAvailability of Report & Accounts
8th Mar 20117:00 amRNSRe: 2009 Group Executive Shared Ownership Plan
4th Mar 20117:00 amRNSPreliminary Results
1st Feb 201111:06 amRNSNotification of Results
7th Jan 20114:02 pmRNSHolding(s) in Company
4th Jan 20117:00 amRNSAcquisition
21st Dec 201010:45 amRNSHolding(s) in Company
21st Dec 20107:00 amRNSHolding(s) in Company
16th Dec 20107:00 amRNSChange of Adviser
6th Dec 20107:00 amRNSPost Year End Trading Update
27th Jul 20107:00 amRNSInterim Results
3rd Feb 20107:00 amRNSInterim Results
21st Jan 201010:36 amRNSContract Win
15th Jan 20102:59 pmRNSREPLACEMENT: Notice of Results
15th Jan 201010:35 amRNSNotice of Results
11th Nov 200910:59 amRNSResult of AGM
5th Nov 20097:00 amRNSTrading Update
9th Sep 20097:00 amRNSPreliminary Results
16th Jun 20097:00 amRNSStructural and Strategic Reorganisation
4th Feb 20097:00 amRNSInterim Results
16th Jan 200912:06 pmRNSNotification of Results
3rd Sep 20087:00 amRNSPreliminary Results
6th Feb 20087:01 amRNSInterim Results
16th Jan 20087:00 amRNSNotification of Results
6th Dec 20071:09 pmRNSCanc of AIM trading facility
6th Dec 20079:56 amRNSOffer Update
30th Nov 20077:01 amRNSOffer Update
29th Nov 20077:01 amRNSOffer Update
26th Nov 200712:34 pmRNSResult of EGM
23rd Nov 20079:57 amRNSRule 8.1- Synexus
19th Nov 20079:40 amRNSRule 8.1- Synexus
16th Nov 200710:00 amRNSRule 8.1- Synexus
15th Nov 20073:00 pmBUSRule 8.3 - Synexus Clinincal Research Plc
15th Nov 200712:07 pmBUSRule 8.3 - Synexus Clinical Research Plc
15th Nov 20079:16 amRNSRule 8.1- Synexus
14th Nov 20073:21 pmBUSRule 8.3 - Synexus Clinical Research Plc
13th Nov 20073:16 pmBUSRule 8.3 - Synexus Clinical Research Plc
7th Nov 20074:38 pmRNSOffer Document Posted
7th Nov 20077:02 amRNSOffer for Synexus
6th Nov 20079:10 amRNSRule 8.3- Synexus
22nd Oct 200710:46 amRNSHolding(s) in Company
19th Oct 20076:21 pmRNSResponse to price movement
28th Sep 20077:02 amRNSPre Close Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.